NeoGenomics, Inc. Cash and Cash Equivalents
NeoGenomics, Inc. (NEO) had Cash and Cash Equivalents of $145.54 million as of 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-07-28
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $145.54M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $146.14M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $159.62M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $164.12M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $145.54M 10-Q · filed 2026-07-28 |
| 2026-03-31 | $146.14M 10-Q · filed 2026-04-28 |
| 2025-12-31 | $159.62M 10-Q · filed 2026-07-28 |
| 2025-09-30 | $164.12M 10-Q · filed 2025-10-28 |
| 2025-06-30 | $154.72M 10-Q · filed 2025-07-29 |
| 2025-03-31 | $346.19M 10-Q · filed 2025-04-29 |
| 2024-12-31 | $367.01M 10-K · filed 2026-02-17 |
| 2024-09-30 | $361.99M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $355.08M 10-Q · filed 2024-07-30 |
| 2024-03-31 | $331.91M 10-Q · filed 2024-04-30 |
| 2023-12-31 | $342.49M 10-K · filed 2025-02-18 |
| 2023-09-30 | $306.24M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $289.07M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $275.61M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $263.18M 10-K · filed 2024-02-20 |
| 2022-09-30 | $266.13M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $283.64M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $305.90M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $316.83M 10-K · filed 2023-02-24 |
| 2021-09-30 | $340.56M 10-Q · filed 2022-11-08 |
| 2021-06-30 | $368.80M 10-Q · filed 2022-08-09 |
| 2021-03-31 | $611.97M 10-Q · filed 2022-05-09 |
| 2020-12-31 | $228.71M 10-K · filed 2023-02-24 |
| 2020-09-30 | $233.23M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $295.28M 10-Q · filed 2021-08-09 |
| 2020-03-31 | $86.25M 10-Q · filed 2021-05-06 |
| 2019-12-31 | $173.02M 10-K · filed 2022-02-25 |
| 2019-09-30 | $178.89M 10-Q · filed 2020-10-29 |
| 2019-06-30 | $167.44M 10-Q · filed 2020-07-31 |
| 2019-03-31 | $13.20M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $9.81M 10-K · filed 2021-02-25 |
| 2018-09-30 | $118.44M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $9.44M 10-Q · filed 2018-08-06 |
| 2018-03-31 | $15.17M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $12.82M 10-K · filed 2019-02-26 |
| 2017-09-30 | $12.21M 10-Q · filed 2018-11-06 |
| 2017-06-30 | $10.93M 10-Q · filed 2018-08-06 |
| 2017-03-31 | $11.04M 10-Q · filed 2018-05-08 |
| 2016-12-31 | $12.53M 10-K · filed 2019-02-26 |
| 2016-09-30 | $28.93M 10-Q · filed 2017-11-13 |
| 2016-06-30 | $21.79M 10-Q · filed 2017-08-07 |
| 2016-03-31 | $19.26M 10-Q · filed 2017-05-09 |
| 2015-12-31 | $23.42M 10-K · filed 2019-02-26 |
| 2015-09-30 | $33.97M 10-Q · filed 2016-11-07 |
| 2015-06-30 | $32.95M 10-Q · filed 2016-08-05 |
| 2015-03-31 | $31.25M 10-Q · filed 2016-05-10 |
| 2014-12-31 | $33.69M 10-K · filed 2018-03-13 |
| 2014-09-30 | $34.37M 10-Q · filed 2015-11-06 |
| 2014-06-30 | $5.02M 10-Q · filed 2015-07-31 |
| 2014-03-31 | $5.38M 10-Q · filed 2015-05-11 |
| 2013-12-31 | $4.83M 10-K · filed 2017-03-14 |
| 2013-09-30 | $4.93M 10-Q · filed 2014-11-04 |
| 2013-06-30 | $4.64M 10-Q · filed 2014-07-29 |
| 2013-03-31 | $4.63M 10-Q · filed 2014-05-12 |
| 2012-12-31 | $1.87M 10-K · filed 2016-04-18 |
| 2012-09-30 | $2.04M 10-Q · filed 2013-10-30 |
| 2012-06-30 | $2.57M 10-Q · filed 2013-08-02 |
| 2012-03-31 | $2.76M 10-Q · filed 2013-05-13 |
| 2011-12-31 | $2.63M 10-K · filed 2015-03-03 |
| 2011-09-30 | $2.65M 10-Q · filed 2012-11-05 |
| 2011-06-30 | $2.63M 10-Q/A · filed 2012-08-15 |
| 2011-03-31 | $2.53M 10-Q · filed 2012-05-14 |
| 2010-12-31 | $1.10M 10-K · filed 2014-02-24 |
| 2010-09-30 | $1.55M 10-Q · filed 2011-10-25 |
| 2010-06-30 | $2.18M 10-Q/A · filed 2011-08-01 |
| 2009-12-31 | $1.63M 10-K · filed 2012-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |